Immunome (Nasdaq: IMNM), a US clinical-stage biotechnology company, announced that it has entered into an exclusive licensing agreement with Israel-based Nectin Therapeutics for the rights to a panel of antibodies targeting undisclosed targets.
“This agreement allows Nectin to further focus and realize value from our first-in-class anti-PVR program (NTX1088) through ongoing clinical trials in tumor types with high unmet need, as well as advance our novel ADCs into clinical development. Immunome’s leadership team has a proven track record of developing and commercializing novel ADC therapies, making them the ideal partner to advance these promising assets,” said Fabian Tenenbaum, Chief Executive Officer of Nectin Therapeutics.
“Immunome believes that by combining high-quality antibodies with innovative linker-payload technology, we will be able to deliver the next generation of innovative antibody-drug conjugates to address novel targets,” said Clay Segal, president and CEO of Immunome, adding, “We appreciate the work Nectin has done with these antibodies and look forward to moving forward.”
This article is available to registered users only. To continue reading, please sign up for free. Your free trial will give you access to one week of exclusive features, interviews, roundups and commentary from some of the sharpest minds in the pharma and biotechnology sector. If you’re already a registered user, please log in. If your trial has expired, you can sign up here.
Log in to your account
Try before you buy
free
7-day trial access
Try our free trial. We bring you all the news that matters in the world of pharma and biotech. Exclusive features, podcasts, interviews, data analysis and commentary from our global network of life sciences journalists. Receive The Pharma Letter’s daily breaking news bulletins, free forever.
Become a subscriber
£820
Or £77 per month
Subscribe now Get unlimited access to leading pharma and biotech news, commentary and analysis. Latest updates on clinical trials, conferences, M&A, licensing, funding, regulatory, patent and legal, executive appointments, commercial strategies and financial results. A daily roundup of major pharma and biotech events. An in-depth monthly briefing on executive appointments and M&A news. Choose from our cost-effective annual package or flexible monthly subscriptions. Pharma Letter is a highly useful and valuable life sciences service that brings together daily updates on performance, talent and products. It’s a vital piece of information to keep you informed.
Chairman of Sanofi-Aventis UK
Sign up to receive email updates
Get daily news from leaders in biotech and pharmaceuticals
